Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Independent of this activity, PD-L1 has been recently shown to also exert a cancer cell-intrinsic function promoting tumorigenesis.
|
31722999 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
|
31208922 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Programmed death ligand 1 (PD-L1) is expressed in many malignancies and plays a critical role in escape from immune surveillance through inhibition of its receptor programmed death 1.
|
31410753 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Additional end points were progression-free survival (PFS), toxicity, biomarkers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy quality-of-life (QOL) metrics using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 and the Brief Fatigue Inventory.
|
31721643 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This phenomenon seems to occur with both anti-cytotoxic T-lymphocyte-associated protein 4 and anti-programmed death-1/programmed death ligand-1, and across different solid malignancies.
|
31727344 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The authors examined the performance of PD-L1 immunostaining in liquid-based cytology (LBC) to determine whether it could be a biomarker of malignancy or aggressive disease.
|
31821747 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer immunotherapy, particularly a class of antibodies targeting the CTLA4 and PD-1/PD-L1 negative regulators of immune response (collectively called the immune checkpoint), is one of the most promising approaches for cancer treatment and the use of immune checkpoint inhibitors (ICI) has demonstrated remarkable success in several types of cancer.
|
31502147 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This has led to the development of drugs that block distinct immune checkpoints, such as Programmed Death 1 (PD-1) and its major ligand PD-L1, that have shown great promise in treating diverse types of cancer.
|
31839609 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The immune checkpoint inhibitors (ICPIs) agents anti-T lymphocytes-associated antigen 4 (CTLA-4) and anti-programmed cell death protein-1 (PD-1) and its ligands (PD-L1/PD-L2) have opened a new scenario in the treatment of cancer.
|
31542865 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Immune check-point inhibitors such as anti-PD-1/PD-L1 antibodies have proved successful for mismatch repair-deficient endometrial cancers and HPV-targeted therapies are under development for HPV-related malignancies.
|
31846530 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous studies found that programmed cell death 1 ligand 1 (PD-L1) was associated with chemoresistance of cancer.
|
31777260 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We highlight the convergence of mesenchymal traits and PD-L1 expression and examine the functions of this immune inhibitory molecule, which confers cancer cell resistance and aggressiveness.
|
31422157 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PD-L1 Inhibitor-Induced Thyroiditis is Associated with Better Overall Survival in Cancer Patients.
|
31813343 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is a negative immune checkpoint pathway that inhibit immune responses, and upregulation of this pathway has implications in many malignancies.
|
31761384 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the multivariate analysis, PD-L1 expression in both cancer and stroma cells (HR 2.20; P = 0.002) was an independent predictor of poor overall survival.
|
31407173 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The clinical therapy that dilapidates PD1 or PD-L1-mediated cancer tolerance has pushed out the need to uncover the molecular regulation of PD-L1 overexpression in the tumor cell.
|
30385408 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunotherapy targeting immune checkpoints, such as PD-L1, has demonstrated significant success in controlling numerous malignancies.
|
31030234 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The combination of PD-1/PD-L1 blockade and macrophage-targeted therapy will exert synergetic anti-tumor effect and shape the future of cancer immunology and immunotherapy.
|
30963235 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Programmed death ligand-1 (PD-L1) in conjunction with tumor-infiltrating lymphocytes (TILs) has been studied as a potential mechanism of "immune escape" in several human malignancies.
|
30085020 |
2019 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
|
31305264 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Among these checkpoints are tytotoxic T-lymphocyte-associated antigen 4, checkpoints programmed death-1 and programmed death-ligand 1; their blockades have been approved by the Food and Drug Administration for therapy of melanoma and other types of cancers.
|
30137232 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemical expression of HDAC6, hypoxia inducible factors-1α (HIF-1α), programmed death-1 ligand (PD-L1), CD44 (cancer stem cell marker), and ARID1A was analysed for 106 OCCC patients.
|
30787326 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study suggests that blocking PD1/PDL1 pathway may become an effective mode of treatment in cancer immunotherapy especially for Renal Cell Carcinomas.
|
31653140 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mut-p53-induced epithelial-mesenchymal transition (EMT) plays a crucial role in the invasion and metastasis of endocrine carcinomas, and Mut-p53 is involved in cancer immune evasion by upregulating PD-L1 expression.
|
30915036 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The success of T cell-directed checkpoint inhibitors of CTLA-4 and PD-1/PD-L1 has opened a new approach for cancer immunotherapy and resulted in extensive research on immune checkpoints.
|
31681269 |
2019 |